About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

RECRUITINGNA

Closed-Loop Impact on Chronic Kidney Disease in Type 2 Diabetes

The Effect of Fully Closed-loop Insulin Delivery on Renal Oxygenation in People With Type 2 Diabetes and Chronic Kidney Disease: an Open-label, Single-center, Randomized Two-arm Parallel Trial

NCT06925217•Heba Al-Alwan

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Type 2 DiabetesChronic Kidney Disease Stage 3

Interventions

CamAPS HX

Standard insulin therapy with CGM

Locations

2

Switzerland

Locations (2)

Centre Hospitalier Universitaire Vaudois

Lausanne, Canton of Vaud, Switzerland

CHUV

Lausanne, Switzerland

Key Dates

Start Date

June 16, 2025

Primary Completion Date

May 1, 2027

Completion Date

May 1, 2027

Last Updated

February 12, 2026

Related Studies

An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea

NCT07232537

Chronic Kidney DiseaseType 2 Diabetes Mellitus

Capillary OGTT Study

NCT06815081

Type 1 Diabetes (T1D)Type 2 Diabetes

RECRUITINGPhase 4

GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH

NCT06003153

Genetic PredispositionMetabolic Diseases+1 more

RECRUITINGPhase 1/2

A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)

NCT06721143

Chronic Kidney Disease Stage 3

An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

NCT06278207

Chronic Kidney DiseaseType 2 Diabetes Mellitus

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View all related studies

Contacts

Heba Al-Alwan, MD, PhD

CONTACT

+4179 556 27 98 heba.al-alwan@chuv.ch

Sponsors

Lead Sponsor

Heba Al-Alwan

Collaborators

Swiss National Science Foundation
Institute of Primary Health Care (BIHAM), Switzerland

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 12, 2026Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions